A vaccine against respiratory syncytial virus (RSV) was effective at preventing RSV-associated illness among older adults and the children of vaccinated mothers, based on interim results from 2 phase 3 trials. If licensed, the vaccine, an intramuscular injection that contains a combination of prefusion F glycoproteins from RSV A and B, would be the first available for RSV.
Source: JAMA Online First